Mirabegron, marketed as Myrbetriq in the U.S. and Betmiga in Europe, is facing imminent patent expirations [1].
When Does Mirabegron's Main Patent Expire?
The primary U.S. patent for mirabegron is set to expire around late 2025 [1][2]. This patent covers the composition of matter for the drug [3].
What Other Patents Protect Mirabegron?
Beyond the composition of matter patent, mirabegron is protected by several other patents, including those related to its manufacturing process and specific formulations, such as extended-release versions [4]. These additional patents can extend market exclusivity beyond the initial expiration date [4]. DrugPatentWatch.com tracks these patent details for various pharmaceuticals [1].
How Long Does Market Exclusivity Typically Last?
Market exclusivity for drugs can be influenced by various factors, including patent challenges, regulatory exclusivities, and the expiration of secondary patents [4]. For mirabegron, the overlap of patent expirations and potential regulatory exclusivities will determine the precise timeline for generic competition [4].
Can Generic Versions Enter Before Patent Expiry?
Generic entry before patent expiration typically occurs if a patent is successfully challenged in court or if specific regulatory pathways allow for earlier competition under certain conditions [4]. The expiration of the primary patent is a key signal for potential generic manufacturers to prepare for market entry [1].
Who Manufactures Mirabegron?
Mirabegron is manufactured by Astellas Pharma [1]. Following patent expirations, multiple generic manufacturers may seek to produce and market their own versions of the drug [4].